HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hartung, H.-P. Articles by Toyka, K. V. Search for Related Content PubMed PubMed Citation Articles by Hartung, H.-P. Articles by Toyka, K. V.

Guillain-barré syndrome

Activated complement components C3a and C5a in CSF

Department of Neurology (Drs. Hartung and Toyka and Ms. Schwenke), University of Düsseldorf, and the Institute of Medical Microbiology (Dr. Bitter-Suermann), University of Mainz, West Germany.

Plasma and spinal fluid levels of complement activation products C3a and C5a were quantitated by radioimmunoassay in a group of 16 patients suffering from acute monophasic Guillain-Barré syndrome (GBS). Median CSF levels of C3a (118 ng/ml) and of C5a (9.6 ng/ml) were significantly elevated when compared with samples from a control group of patients with noninflammatory neurologic diseases. Plasma concentrations of these anaphylatoxic peptides were not significantly different between the two populations. Our findings indicate that the complement system is activated in the CSF of patients with acute GBS. Complement activation products may contribute to the inflammatory changes observed in this disorder.

Address correspondence and reprint requests to Dr. Hartung, Department of Neurology, University of Düsseldorf, Moorenstrasse 5, D-4000 Düsseldorf 1, West Germany.

Presented in part at the thirty-eighth annual meeting of the American Academy of Neurology, New Orleans, LA, April 1986.

Supported by grants from the Ministerium f. Wissenschaft u. Forschung, NRW, and Hertie Stiftung.

Received July 22, 1986. Accepted for publication in final form September 25, 1986.

This article has been cited by other articles:

				S. K. Halstead, F. M. P. Zitman, P. D. Humphreys, K. Greenshields, J. J. Verschuuren, B. C. Jacobs, R. P. Rother, J. J. Plomp, and H. J. Willison Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model Brain, May 1, 2008; 131(5): 1197 - 1208. [Abstract] [Full Text] [PDF]

				H. C. Lehmann and H.-P. Hartung Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies Brain, May 1, 2008; 131(5): 1168 - 1170. [Full Text] [PDF]

				K. Geleijns, A. Roos, J. J. Houwing-Duistermaat, W. van Rijs, A. P. Tio-Gillen, J. D. Laman, P. A. van Doorn, and B. C. Jacobs Mannose-Binding Lectin Contributes to the Severity of Guillain-Barre Syndrome J. Immunol., September 15, 2006; 177(6): 4211 - 4217. [Abstract] [Full Text] [PDF]

				J. Wanschitz, H. Maier, H. Lassmann, H. Budka, and T. Berger Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome Brain, September 1, 2003; 126(9): 2034 - 2042. [Abstract] [Full Text] [PDF]

				K.H. Wollinsky, P.-J. Hulser, H. Brinkmeier, P. Aulkemeyer, W. Bossenecker, K.-H. Huber-Hartmann, P. Rohrbach, H. Schreiber, F. Weber, M. Kron, et al. CSF filtration is an effective treatment of Guillain-Barre syndrome: A randomized clinical trial Neurology, September 11, 2001; 57(5): 774 - 780. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]